High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Trends in primary central nervous system lymphoma incidence and survival in the U.S.Registry Study · 2016 · 268 citations
2Treatment for Primary CNS Lymphoma: The Next StepOriginal Research · 2000 · 605 citations
3Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS StudyEarly-Phase Clinical Trial · 2019 · 287 citations
4Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialCohort Study · 2016 · 615 citations
5High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS LymphomaEarly-Phase Clinical Trial · 2006 · 298 citations
6High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous systemOriginal Research · 2007 · 206 citations
7Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS LymphomaHuman Clinical Trial · 2005 · 918 citations
8High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)Late-Phase Clinical Trial · 2016 · 70 citations
9Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: long-term efficacy and endocrine analysisBlood Advances · 2026
10Quantitative and mutational properties in the ctDNA uncovered by systemic inflammation in large B-cell lymphomaBlood Advances · 2026

More from Blood Advances

More from University of Freiburg